SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

June 28, 2016 07:00 ET

CTD Holdings Announces Joint Presentation With UCSF Benioff Children's Hospital Oakland on Patient Experience in Compassionate Treatment Program

Presentation Reviews Results of Niemann-Pick Type C Disease Treatment With IV Cyclodextrins

ALACHUA, FL--(Marketwired - June 28, 2016) - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced a joint video presentation with UCSF Benioff Children's Hospital Oakland on Niemann-Pick Type C (NPC) patient experience in a compassionate treatment program.

The presentation, which is posted on CTD's website, reviews the history of CTD's clinical program and provides data made available for the first time on compassionate use of CTD's hydroxypropyl beta cyclodextrin, Trappsol ® Cyclo ™ in NPC disease. The presentation features Dr. Sharon Hrynkow, CTD Senior Vice President for Medical Affairs, and Dr. Caroline Hastings, pediatric hematologist/oncologist at UCSF Benioff Children's Hospital Oakland. Dr. Hastings is the first physician in the United States to use cyclodextrins in the treatment of NPC in children under compassionate use.

"In the 11 NPC patients described in the presentation, intravenous administration of cyclodextrins was well tolerated and its safety profile allowed compassionate use of IV cyclodextrins for more than six years in some cases," said Dr. Hastings. "Anecdotal evidence showed impacts on neurologic, lung and liver function, and on behavior, gross and fine motor skills, and speech. Half of the families reported improved quality of life overall."

Dr. Hrynkow added: "We are grateful to the nine physicians from the US and Brazil and especially to the NPC families for allowing us to share their experience with IV cyclodextrins used compassionately. Without the support of the families and their caregivers, this presentation would not have been possible."

NPC disease is a rare and fatal genetic disease. It impacts primarily children but is also increasingly diagnosed in older patients who may live with this disability for many years. NPC impacts the brain and major organs through abnormal accumulation of cholesterol in cells. CTD is working to obtain regulatory approval of its orphan drug designated Trappsol® Cyclo™ for the treatment of NPC.

"This presentation provides background on CTD's work with the NPC community since 2008 and shows the promising results of IV cyclodextrin treatment in NPC patients," said CTD Chairman and CEO N. Scott Fine. "Our commitment to helping patients and their families around the world combat this devastating disease is long-standing. We look forward to continuing to work closely with families and physicians on all aspects of our clinical program."

Click here to view the CTD-UCSF Benioff Children's Hospital Oakland presentation video on NPC patient experience.

About the Company:
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information